Is BPC-157 Legal in Michigan? How to Access It Through Legal Channels

Print or save as PDF

See the public record for BPC-157

What is BPC-157's federal status?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. No FDA-approved drug contains it, no US Pharmacopeia or National Formulary monograph exists for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. Websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'; those products are not FDA-approved drugs [1].

Can a pharmacy compound it?

BPC-157 is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), including category 1, the group FDA says it generally will not act against compounders for if the conditions are met [2]. It is also not on FDA's list for outsourcing facilities, the larger registered compounders [3].

It sat in category 2, FDA's table of substances that may present significant safety risks, from September 2023 until April 22, 2026, and came off because the groups that nominated it withdrew, not because FDA cleared it [7][6]. FDA's stated concerns remain on that page: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', plus peptide-related impurities and characterization of the active ingredient, and the agency said it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [7].

What does the October 2026 draft HHS policy say?

HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy covering six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026, with public comments open for two weeks after publication [5][6]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [5].

The conditions for BPC-157 are: the acetate form only, in subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed); a single active ingredient; bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard; a label reading 'This is a compounded drug product. Not for resale.'; a patient-specific prescription; serious adverse events and quality problems reported to FDA MedWatch; an FDA 510(k)-cleared syringe as the only co-packaged device; and documentation of adequate bioavailability for oral forms [6].

The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue appears [6].

Separately, FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation. The vote is advice only, and adding BPC-157 would need formal rulemaking [8][6].

Is BPC-157 safe, and is it allowed in sport?

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and its search of the adverse-event database through December 4, 2025 found three reports, all involving injectable BPC-157, which FDA said it cannot tell were caused by the drug [1]. A 2026 systematic review of human evidence found three studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low [10]. WADA names BPC-157 in class S0 (non-approved substances), prohibited at all times, in a 2026 List in force since January 1, 2026 [9].